

Cleveland BioLabs – QuickView

15 January 2013

Investment summary: First line of (bio)defence

Cleveland BioLabs' biodefence franchise is fundamental to its near-term investment case and 2013 should see significant progress in the development of Entolimod (CBLB502) as the first available treatment for acute radiation syndrome (ARS). A potential development funding contract from BARDA in H113 is a major stock catalyst and financing event. Pivotal studies in animals and humans are planned for 2013 and a BLA submission is targeted for Q414. Entolimod, a TLR5 agonist, also holds potential as an anti-cancer agent, with a Phase I study to complete in Q413.

Animal efficacy rules OK

The FDA created the Animal Efficacy Rule in 2002 to encourage and enable the development of new products when human efficacy studies are not ethical or feasible. To date, four products have been approved under this pathway, two gaining approval in 2012 (raxibacumab for inhalational anthrax and levofloxacin for plague), confirming the viability of this regulatory process for Entolimod.

Efficacy in animals, safety in humans

A pivotal study of Entolimod in 179 non-human primates (single im admin 25 hours after total body irradiation) demonstrated efficacy at the highest-anticipated radiation level requested by the FDA (60-day survival rate of 75% for Entolimod vs 28% placebo), a dose response and validation of biomarkers (G-CSF and IL-6). Human safety trials have been completed in 150 healthy volunteers and Cleveland is planning further pivotal animal efficacy and human safety studies through 2013. A pre-emergency use authorisation (EUA) submission is also targeted for Q313; most countermeasures stockpiled by the US government are procured through an EUA.

Longer-term oncology play

Entolimod's TLR5 agonist activity delivers protective qualities (via healing cytokines/anti-apoptotic factors) but also mobilises an innate immune response, particularly against TLR5+ tumours (eg liver, breast, colon, lung). Cleveland is conducting a Phase I study of Entolimod in [48-patients](#) with unresectable solid tumours, with results due in H114. Two further oncology candidates (CBL0137 and CBL0102) are also undergoing Phase I studies through a Russian subsidiary, Incuron.

Valuation: Undemanding \$35m EV

With \$35m cash after a \$13.8m public offering in October 2012, Cleveland's EV of \$35m is undemanding with potential upside from a BARDA contract in H113. The stock may also offer an attractive entry point with a view to Cleveland's future in oncology. We intend to initiate full coverage of Cleveland BioLabs in due course.

Consensus estimates

Year End	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/10	15.3	(26.7)	(1.01)	0.0	N/A	N/A
12/11	8.8	(5.2)	(0.12)	0.0	N/A	N/A
12/12e	1.9	(33.8)	(0.92)	0.0	N/A	N/A
12/13e	2.0	(36.6)	(0.76)	0.0	N/A	N/A

Price **\$1.56**
Market cap **\$70m**

Share price graph



Share details

Code **CBLI**
Listing **NASDAQ**
Sector **Pharma & biotech**
Shares in issue **44.5m**

Business

Cleveland BioLabs is a clinical-stage US biotechnology company focused on oncology and the mitigation of radiation injury. Cleveland's lead compound, Entolimod (CBLB502), is being developed as both a radiation countermeasure (pivotal studies) and a cancer treatment (Phase I study in advanced solid tumours).

Bull

- Entolimod to become first approved and stockpiled product for ARS.
- Entolimod's anti-cancer potential adds to an emerging cancer portfolio.
- US government contracts provide major non-dilutive finance.

Bear

- Failure to win BARDA contract adds near-term fresh financing pressure.
- US government contracts hard to predict/fickle, adds uncertainty.
- Early-stage cancer pipeline yet to provide proof-of-concept data

Analysts

Christian Glennie +44 (0)20 3077 5727
Robin Davison +44 (0)20 3077 5737

healthcare@edisoninvestmentresearch.co.uk

QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

EDISON INVESTMENT RESEARCH LIMITED

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Cleveland BioLabs prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority. www.edisoninvestmentresearch.co.uk. Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

London +44 (0)20 3077 5700
Lincoln House, 296-302 High Holborn
London, WC1V 7JH, UK

New York +1 646 653 7026
245 Park Avenue, 24th Floor
NY 10167, New York, US

Wellington + 64 4894 8555
Level 15 HP Tower, 171 Featherston St
Wellington 6011, NZ

Sydney +61 (0)2 9258 1162
Level 33, Australia Square, 264 George St,
Sydney, NSW 2000, Australia